Jonathan I. Epstein

93.4k total citations · 25 hit papers
991 papers, 63.6k citations indexed

About

Jonathan I. Epstein is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, Jonathan I. Epstein has authored 991 papers receiving a total of 63.6k indexed citations (citations by other indexed papers that have themselves been cited), including 705 papers in Pulmonary and Respiratory Medicine, 353 papers in Rheumatology and 343 papers in Surgery. Recurrent topics in Jonathan I. Epstein's work include Prostate Cancer Diagnosis and Treatment (512 papers), Prostate Cancer Treatment and Research (481 papers) and Urologic and reproductive health conditions (338 papers). Jonathan I. Epstein is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (512 papers), Prostate Cancer Treatment and Research (481 papers) and Urologic and reproductive health conditions (338 papers). Jonathan I. Epstein collaborates with scholars based in United States, Canada and Italy. Jonathan I. Epstein's co-authors include Patrick C. Walsh, Alan W. Partin, Mahul B. Amin, Lars Egevad, John R. Srigley, Peter A. Humphrey, Bruce J. Trock, Angelo M. De Marzo, Misop Han and Brett Delahunt and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jonathan I. Epstein

979 papers receiving 61.5k citations

Hit Papers

The 2014 International ... 1988 2026 2000 2013 2015 1998 2015 2001 2001 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    2015 2.2k citations Jonathan I. Epstein, Lars Egevad et al. The American Journal of Surgical Pathology profile →
  2. The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder
    1998 1.2k citations Jonathan I. Epstein, Mahul B. Amin et al. The American Journal of Surgical Pathology profile →
  3. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
    2015 945 citations Jonathan I. Epstein, Lars Egevad et al. profile →
  4. LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
    2001 821 citations Alan W. Partin, Jonathan I. Epstein et al. profile →
  5. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
    2001 755 citations Alan W. Partin, Leslie A. Mangold et al. profile →
  6. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
    2013 738 citations John R. Srigley, Brett Delahunt et al. The American Journal of Surgical Pathology profile →
  7. Proliferative Inflammatory Atrophy of the Prostate
    1999 662 citations Angelo M. De Marzo, Jonathan I. Epstein et al. American Journal Of Pathology profile →
  8. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.
    1994 641 citations Jonathan I. Epstein, G. Steven Bova et al. profile →
  9. Correlation of pathologic findings with progression after radical retropubic prostatectomy
    1993 618 citations Jonathan I. Epstein, Patrick C. Walsh et al. profile →
  10. Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer
    2003 559 citations Alan W. Partin, Jonathan I. Epstein et al. The Journal of Urology profile →
  11. Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years
    1994 555 citations Patrick C. Walsh, Alan W. Partin et al. The Journal of Urology profile →
  12. Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer
    2003 554 citations Alan W. Partin, Jonathan I. Epstein et al. The Journal of Urology profile →
  13. Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia
    1990 506 citations Alan W. Partin, Jonathan I. Epstein et al. The Journal of Urology profile →
  14. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
    2011 485 citations Patricia Landis, Zhaoyong Feng et al. Journal of Clinical Oncology profile →
  15. PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
    1997 484 citations Alan W. Partin, Jonathan I. Epstein et al. profile →
  16. Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades
    2012 477 citations Jonathan I. Epstein, Zhaoyong Feng et al. profile →
  17. Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical Prostatectomy
    1988 477 citations Jonathan I. Epstein, Charles B. Brendler et al. The Journal of Urology profile →
  18. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
    1993 474 citations Alan W. Partin, Jonathan I. Epstein et al. profile →
  19. Prediction of Progression Following Radical Prostatectomy
    1996 457 citations Jonathan I. Epstein, Alan W. Partin et al. The American Journal of Surgical Pathology profile →
  20. Prognostic G leason grade grouping: data based on the modified G leason scoring system
    2013 452 citations Patrick C. Walsh, Alan W. Partin et al. profile →
  21. An Update of the Gleason Grading System
    2009 380 citations Jonathan I. Epstein The Journal of Urology profile →
  22. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
    2014 375 citations Jonathan I. Epstein, Mahul B. Amin et al. The American Journal of Surgical Pathology profile →
  23. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer
    2015 365 citations Jonathan I. Epstein, Patricia Landis et al. Journal of Clinical Oncology profile →
  24. Genomic and phenotypic heterogeneity in prostate cancer
    2020 307 citations Michael C. Haffner, William G. Nelson et al. profile →
  25. Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update
    2013 305 citations Jonathan I. Epstein, Rodolfo Montironi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan I. Epstein United States 121 46.9k 16.6k 15.9k 12.3k 8.6k 991 63.6k
Peter T. Scardino United States 124 40.7k 0.9× 10.6k 0.6× 10.1k 0.6× 8.2k 0.7× 7.1k 0.8× 738 52.0k
Peter R. Carroll United States 110 30.7k 0.7× 6.2k 0.4× 10.2k 0.6× 7.8k 0.6× 7.5k 0.9× 880 46.0k
Alan W. Partin United States 94 31.0k 0.7× 7.9k 0.5× 6.5k 0.4× 7.6k 0.6× 4.9k 0.6× 657 40.3k
Patrick C. Walsh United States 104 29.5k 0.6× 9.4k 0.6× 8.0k 0.5× 5.8k 0.5× 3.9k 0.5× 577 40.5k
Victor E. Reuter United States 105 24.2k 0.5× 3.8k 0.2× 12.4k 0.8× 16.4k 1.3× 7.8k 0.9× 509 41.7k
Theodorus van der Kwast Netherlands 86 20.0k 0.4× 4.4k 0.3× 7.9k 0.5× 8.2k 0.7× 5.1k 0.6× 651 32.9k
Michael L. Blute United States 100 28.4k 0.6× 3.8k 0.2× 9.7k 0.6× 13.0k 1.1× 6.6k 0.8× 507 36.2k
Shahrokh F. Shariat United States 113 21.8k 0.5× 3.9k 0.2× 38.1k 2.4× 9.7k 0.8× 11.8k 1.4× 1.7k 58.7k
Rodolfo Montironi Italy 77 16.3k 0.3× 4.3k 0.3× 10.3k 0.6× 9.7k 0.8× 5.9k 0.7× 877 30.3k
William J. Catàlona United States 90 20.9k 0.4× 6.7k 0.4× 8.0k 0.5× 4.8k 0.4× 4.4k 0.5× 547 31.2k

Countries citing papers authored by Jonathan I. Epstein

Since Specialization
Citations

This map shows the geographic impact of Jonathan I. Epstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan I. Epstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan I. Epstein more than expected).

Fields of papers citing papers by Jonathan I. Epstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan I. Epstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan I. Epstein. The network helps show where Jonathan I. Epstein may publish in the future.

Co-authorship network of co-authors of Jonathan I. Epstein

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan I. Epstein. A scholar is included among the top collaborators of Jonathan I. Epstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan I. Epstein. Jonathan I. Epstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Low, Jin‐Yih, Minjeong Ko, Brian Hanratty, et al.. (2022). Genomic Characterization of Prostatic Basal Cell Carcinoma. American Journal Of Pathology. 193(1). 4–10. 4 indexed citations
2.
Spieker, Andrew J., Tarik Gheit, Michaël Herfs, et al.. (2022). Pathological characterization and clinical outcome of penile intraepithelial neoplasia variants: a North American series. Modern Pathology. 35(8). 1101–1109. 7 indexed citations
3.
Salles, Daniela C., Douglas A. Mata, & Jonathan I. Epstein. (2020). Significance of Paneth cell–like differentiation in prostatic adenocarcinoma: a retrospective cohort study of 80 cases. Human Pathology. 102. 7–12. 5 indexed citations
4.
Guedes, Liana B., Emmanuel S. Antonarakis, Michael T. Schweizer, et al.. (2017). MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research. 23(22). 6863–6874. 112 indexed citations
5.
Lee, George, Robert W. Veltri, Guangjing Zhu, et al.. (2016). Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. European Urology Focus. 3(4-5). 457–466. 38 indexed citations
6.
Epstein, Jonathan I., Lars Egevad, Mahul B. Amin, et al.. (2015). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American Journal of Surgical Pathology. 40(2). 244–252. 2205 indexed citations breakdown →
7.
Zhu, Guangjing, Zhi Liu, Jonathan I. Epstein, et al.. (2015). A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. Cancer Epidemiology Biomarkers & Prevention. 24(12). 1864–1872. 13 indexed citations
8.
Sood, Anil K., Hameed A. Rahimi, Wenle Wang, et al.. (2013). Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research. 20(4). 890–903. 261 indexed citations
9.
So, Jeffrey & Jonathan I. Epstein. (2013). GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Modern Pathology. 26(10). 1365–1370. 65 indexed citations
10.
Ross, Hillary, Oleksandr N. Kryvenko, Janet E. Cowan, et al.. (2012). Do Adenocarcinomas of the Prostate With Gleason Score (GS)≤6 Have the Potential to Metastasize to Lymph Nodes?. The American Journal of Surgical Pathology. 36(9). 1346–1352. 227 indexed citations
11.
Amin, Ali & Jonathan I. Epstein. (2012). Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Human Pathology. 43(12). 2124–2128. 29 indexed citations
12.
Ross, Ashley E., Stacy Loeb, Patricia Landis, et al.. (2010). Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. Journal of Clinical Oncology. 28(17). 2810–2816. 201 indexed citations
13.
Makarov, Danil V., Sumit Isharwal, Lori J. Sokoll, et al.. (2009). Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer. Clinical Cancer Research. 15(23). 7316–7321. 44 indexed citations
14.
Isharwal, Sumit, Michael Craig Miller, Jonathan I. Epstein, et al.. (2008). Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy. International Journal of Cancer. 123(11). 2636–2643. 21 indexed citations
15.
Veltri, Robert W., Sumit Isharwal, Michael Craig Miller, et al.. (2008). Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. The Prostate. 68(16). 1806–1815. 31 indexed citations
16.
Kleeberger, Wolfram, G. Steven Bova, Matthew E. Nielsen, et al.. (2007). Roles for the Stem Cell–Associated Intermediate Filament Nestin in Prostate Cancer Migration and Metastasis. Cancer Research. 67(19). 9199–9206. 154 indexed citations
17.
Fine, Samson W., Denis M. McCarthy, Theresa Y. Chan, Jonathan I. Epstein, & Pedram Argani. (2006). Malignant solitary fibrous tumor of the kidney: report of a case and comprehensive review of the literature.. Archives of Pathology & Laboratory Medicine. 130(6). 857–861. 57 indexed citations
18.
Srigley, John R., Mahul B. Amin, Liliane Boccon‐Gibod, et al.. (2005). Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. Scandinavian Journal of Urology and Nephrology. 39(sup216). 8–19. 31 indexed citations
19.
Fine, Samson W., Peter A. Humphrey, Louis P. Dehner, Mahul B. Amin, & Jonathan I. Epstein. (2005). UROTHELIAL NEOPLASMS IN PATIENTS 20 YEARS OR YOUNGER: A CLINICOPATHOLOGICAL ANALYSIS USING THE WORLD HEALTH ORGANIZATION 2004 BLADDER CONSENSUS CLASSIFICATION. The Journal of Urology. 174(5). 1976–1980. 76 indexed citations
20.
Smith, Robert C., Alan W. Partin, Jonathan I. Epstein, & Charles B. Brendler. (1996). Extended Followup of the Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer and Extensive Capsular Perforation. The Journal of Urology. 454–457. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter T. Scardino Breakdown of academic impact, for papers by Peter R. Carroll Breakdown of academic impact, for papers by Alan W. Partin Breakdown of academic impact, for papers by Patrick C. Walsh Breakdown of academic impact, for papers by Victor E. Reuter Breakdown of academic impact, for papers by Theodorus van der Kwast Breakdown of academic impact, for papers by Michael L. Blute Breakdown of academic impact, for papers by Shahrokh F. Shariat Breakdown of academic impact, for papers by Rodolfo Montironi Breakdown of academic impact, for papers by William J. Catàlona
Rankless by CCL
2026